Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0780 cardiovascular outcomes trial in ASCVD or high-risk primary prevention
2025-520519-14-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease comparing Laroprovstat with Placebo (2 arms). Primary endpoint: Time to first event of any component of MACE PLUS. Planned start Sep 2025; status: authorised.
02
Drugs
laroprovstat
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on 2025-520519-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520519-14-00.